Literature DB >> 22265002

Etiology of OHSS and use of dopamine agonists.

Sérgio Reis Soares1.   

Abstract

Vascular endothelial growth factor is the factor that causes increased capillary permeability and therefore the most serious manifestations of ovarian hyperstimulation syndrome. Dopamine agonists can both prevent and treat ovarian hyperstimulation syndrome by blocking expression of the vascular endothelial growth factor receptor.
Copyright © 2012 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22265002     DOI： 10.1016/j.fertnstert.2011.12.046

Source DB:  PubMed          Journal:  Fertil Steril        ISSN： 0015-0282            Impact factor:   7.329


  18 in total

1.  A new treatment to avoid severe ovarian hyperstimulation utilizing insights from in vitro maturation therapy.

Authors:  B I Rose
Journal:  J Assist Reprod Genet       Date:  2013-12-01       Impact factor: 3.412

Review 2.  Dopamine agonists for preventing ovarian hyperstimulation syndrome.

Authors:  Huilin Tang; Selma Mourad; Suo-Di Zhai; Roger J Hart
Journal:  Cochrane Database Syst Rev       Date:  2016-11-30

3.  Rare genetic variants potentially involved in ovarian hyperstimulation syndrome.

Authors:  Katrien Stouffs; Sari Daelemans; Samuel Santos-Ribeiro; Sara Seneca; Alexander Gheldof; Ali Sami Gürbüz; Michel De Vos; Herman Tournaye; Christophe Blockeel
Journal:  J Assist Reprod Genet       Date:  2018-11-27       Impact factor: 3.412

4.  Activation of Dopamine D1 Receptors in Dermal Fibroblasts Restores Vascular Endothelial Growth Factor-A Production by These Cells and Subsequent Angiogenesis in Diabetic Cutaneous Wound Tissues.

Authors:  Debanjan Chakroborty; Chandrani Sarkar; Kai Lu; Madhavi Bhat; Partha Sarathi Dasgupta; Sujit Basu
Journal:  Am J Pathol       Date:  2016-07-13       Impact factor: 4.307

5.  Dopamine agonists for preventing ovarian hyperstimulation syndrome.

Authors:  Huilin Tang; Selma M Mourad; Aihua Wang; Suo-Di Zhai; Roger J Hart
Journal:  Cochrane Database Syst Rev       Date:  2021-04-14

6.  Proteomic analysis of human follicular fluid from fertile women.

Authors:  Alberuni M Zamah; Maria E Hassis; Matthew E Albertolle; Katherine E Williams
Journal:  Clin Proteomics       Date:  2015-03-03       Impact factor: 3.988

7.  Effect of varying doses of tamoxifen on ovarian histopathology, serum VEGF, and endothelin 1 levels in ovarian hyperstimulation syndrome: an experimental study.

Authors:  Şehmus Pala; Remzi Atilgan; Zehra Sema Ozkan; Salih Burçin Kavak; Nevin Ilhan; Nusret Akpolat; Ekrem Sapmaz
Journal:  Drug Des Devel Ther       Date:  2015-03-24       Impact factor: 4.162

8.  Low follicular fluid tyrosine concentration in infertile women with ovarian hyperstimulation syndrome.

Authors:  Namiko Amano; Kotaro Kitaya; Sagiri Taguchi; Miyako Funabiki; Yoshihiro Tada; Terumi Hayashi; Yoshitaka Nakamura
Journal:  Biomed Rep       Date:  2014-03-12

9.  Kinase insert domain receptor/vascular endothelial growth factor receptor 2 (KDR) genetic variation is associated with ovarian hyperstimulation syndrome.

Authors:  Travis J O'Brien; Arthur F Harralson; Tuyen Tran; Ian Gindoff; Funda E Orkunoglu-Suer; David Frankfurter; Paul Gindoff
Journal:  Reprod Biol Endocrinol       Date:  2014-05-09       Impact factor: 5.211

10.  Ovarian hyperstimulation syndrome- an optimal solution for an unresolved enigma.

Authors:  Raoul Orvieto
Journal:  J Ovarian Res       Date:  2013-11-05       Impact factor: 4.234
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.